$25.03
+0.93 (+3.86%)
Open$24.35
Previous Close$24.10
Day High$25.79
Day Low$24.35
52W High$26.54
52W Low$5.23
Volume—
Avg Volume260.4K
Market Cap412.69M
P/E Ratio—
EPS$-22.55
SectorBiotechnology
Analyst Ratings
Buy
16 analysts
Price Target
-63.2% upside
Current
$25.03
$25.03
Target
$9.21
$9.21
$5.69
$9.21 avg
$10.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 211.84M | 184.56M | 26.00M |
| Net Income | -394,975,587 | -309,703,805 | 1.01M |
| Profit Margin | -186.5% | -177.1% | 3.9% |
| EBITDA | -391,183,302 | -323,770,811 | 1.64M |
| Free Cash Flow | — | — | 646.8K |
| Rev Growth | +14.8% | +14.8% | +22.0% |
| Debt/Equity | — | — | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |